The approval of VYVGART by Argenx marked a pivotal moment in autoimmune disease treatment. As the pioneering FcRn inhibitor, VYVGART opened doors to novel therapeutic approaches, first in generalized myasthenia gravis (gMG), and now expanding into immune thrombocytopenia (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), and more. Its success has driven momentum across the...